In focus · trending topic

C5

17 stories · following the connections

Akari Therapeutics Demonstrates Positive Response with Coversin in Ongoing Phase 2 PNH Trial and in Additional Clinical Targets

By Nasdaq OMXApr 24, 2017, 11:15 AM UTC

Akari Therapeutics to Present at the Jefferies Complement Symposium

By Nasdaq OMXApr 3, 2017, 11:01 AM UTC

Akari Therapeutics to Present at the Jefferies Complement Symposium

By Nasdaq OMXApr 3, 2017, 11:01 AM UTC

Akari Therapeutics Announces FDA Fast Track Designation For Coversin

By Nasdaq OMXMar 30, 2017, 8:02 PM UTC

Akari Therapeutics Announces R&D Day on April 24, 2017

By Nasdaq OMXMar 17, 2017, 11:00 AM UTC

Akari Therapeutics to Present at the 29th Annual ROTH Conference

By Nasdaq OMXMar 7, 2017, 12:00 PM UTC

Akari Therapeutics to Attend Upcoming Investor Conferences in February

By Nasdaq OMXJan 31, 2017, 12:01 PM UTC

Akari Therapeutics to Attend Upcoming Investor Conferences in February

By Nasdaq OMXJan 31, 2017, 12:01 PM UTC